Ninety-Day Costs, Reoperations, and Readmissions for Primary Total Hip Arthroplasty Patients of Varying Body Mass Index Levels.

BACKGROUND

The purpose of this study is to compare 90-day costs and outcomes for primary total hip arthroplasty patients between a nonobese (body mass index, 18.5-24.9) vs overweight (25-29.9), obese (30-34.9), severely obese (35-39.9), morbidly obese (40-44.9), and super obese (45+) cohorts.

METHODS

We conducted a retrospective review of an institutional database of primary total hip arthroplasty patients from 2006 to 2013. Thirty-three super-obese patients were identified, and the other 5 cohorts were randomly selected in a 2:1 ratio (n = 363). Demographics, 90-day outcomes (costs, reoperations, and readmissions), and outcomes after 3 years (revisions and change scores for Short-Form Health Survey, Harris Hip Score, and Western Ontario and McMaster Universities Arthritis Index) were collected. Costs were determined using unit costs from our institutional administrative data for all in-hospital resource utilization. Comparisons between the nonobese and other groups were made with Kruskal-Wallis tests for non-normal data and chi-square and Fisher exact test for categorical data.

RESULTS

The 90-day costs in the morbidly obese ($13,134 ± $7250 mean ± standard deviation, P < .01) and super-obese ($15,604 ± 6783, P < .01) cohorts were significantly greater than the nonobese cohorts ($10,315 ± 1848). Only the super-obese cohort had greater 90-day reoperation and readmission rates than the nonobese cohort (18.2% vs 0%, P < .01 and 21.2% vs 4.5%, P = .02, respectively). Reoperations and septic revisions after 3 years were greater in the super-obese cohort compared to the nonobese cohort 21.2% versus 3.0% (P = .01) and 18.2% versus 1.5% (P = .01), respectively. Improvements in Short-Form Health Survey, Harris Hip Score, and Western Ontario and McMaster Universities Arthritis Index were comparable in all cohorts.

CONCLUSION

Super-obese patients have greater risks and costs compared to nonobese patients, but also have comparable quality of life improvements.